{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:17:48Z","timestamp":1793755068267,"version":"4.6.1"},"reference-count":89,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Drug Delivery"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/10717544.2022.2161671","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T04:10:23Z","timestamp":1672891823000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application"],"prefix":"10.1080","volume":"30","author":[{"given":"Xiaoming","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Oncology Radiotherapy, Jiangxi Cancer Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine Research Center, The First Affiliated Hospital of Gannan Medical University","place":["Ganzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Songjiang District Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Songjiang District Central Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Breast surgery, Nanchang Third Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-12-158"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.07.039"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz064"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof6020066"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-1948-7"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cocis.2013.06.001"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/nn1023522"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/la504428x"},{"key":"e_1_3_5_10_1","first-page":"354","article-title":"Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module","volume":"6","author":"Chaudhari MB","year":"2016","unstructured":"Chaudhari MB, Desai PP, Patel PA, Patravale VB. (2016). Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module. Drug Deliv Transl Res 6:354\u201364.","journal-title":"Drug Deliv Transl Res"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2016.00057"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11030099"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.0c00313"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2704-2707.2002"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-011-0626-z"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S146315"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10223"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis972"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2014.923956"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010029"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2015.02.010"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi962894z"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2014.898110"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq358"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2019.04.004"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz076"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2006.01.001"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01450-20"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/nn507170s"},{"key":"e_1_3_5_30_1","unstructured":"iCo Therapeutics Inc. (2018). iCo therapeutics announces positive clinical outcome \u2013 Primary endpoint met in Phase 1 Oral Amphotericin B study. Available online: https:\/\/www.newsfilecorp.com\/release\/35503 (accessed on 27 June 2018)."},{"key":"e_1_3_5_31_1","unstructured":"iCo Therapeutics Inc. iCo Therapeutics Inc. (2020). Announces Oral Amphotericin B (iCo 019) update\/appointment of Kishor Wasan as director of research. Available online: https:\/\/www.newsfilecorp.com\/release\/54453 (accessed on 15 April 2020)."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-9841-2"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp300320d"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00249-014-0983-8"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1472-1"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2017.1384520"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.1244"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b04315"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.langmuir.1c00530"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1039\/C5RA10642G"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120688"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2016.1225852"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00724-19"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.06.014"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2017.07.014"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac352"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05784-x"},{"key":"e_1_3_5_48_1","unstructured":"Matinas Biopharma. (2021). Matinas BioPharma announces positive data in the ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis exceeding the prespecified primary endpoint threshold. Available online: https:\/\/www.matinasbiopharma.com\/investors\/news-events\/press-releases\/detail\/403\/matinas-biopharma-announces-positive-data-in-the-ongoing (accessed on 13 September 2021)."},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit588"},{"key":"e_1_3_5_50_1","first-page":"441","article-title":"Preparation, characterization, and cellular uptake of resveratrol-loaded trimethyl chitosan nanoparticles","volume":"27","author":"Min JB","year":"2018","unstructured":"Min JB, Kim ES, Lee JS, Lee HG. (2018). Preparation, characterization, and cellular uptake of resveratrol-loaded trimethyl chitosan nanoparticles. Food Sci Biotechnol 27:441\u201350.","journal-title":"Food Sci Biotechnol"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-017-2249-8"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2008.04.008"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2020.1785050"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69276-5"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.570573"},{"key":"e_1_3_5_56_1","first-page":"198","article-title":"Amphotericin B cochleates: a vehicle for oral delivery","volume":"5","author":"Perlin DS.","year":"2004","unstructured":"Perlin DS. (2004). Amphotericin B cochleates: a vehicle for oral delivery. Curr Opin Investig Drugs 5:198\u2013201.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/1526924820913504"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2016.1228715"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050989"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3339-3342.2003"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2356-2360.2000"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2018.03.015"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5b00028"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.1007.07041"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.05.044"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.111279"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00838-20"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1021\/jp510245n"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.riam.2021.02.001"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b00662"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.0c01505"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.04.009"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425240902802861"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.12.134"},{"key":"e_1_3_5_75_1","unstructured":"U.S. National Library of Medicine. (2015). ClinivalTrials.gov. NCT02629419. CAMB\/MAT2203 in patients with Mucocutaneous Candidiasis. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct02629419 (accessed on 14 December 2015)."},{"key":"e_1_3_5_76_1","unstructured":"U.S. National Library of Medicine. (2020). ClinivalTrials.gov. NCT02971007. Safety and efficacy of oral encochleated Amphotericin B (CAMB\/MAT2203) in the treatment of Vulvovaginal Candidiasis (VVC). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct02971007 (accessed on 22 April 2020)."},{"key":"e_1_3_5_77_1","unstructured":"U.S. National Library of Medicine. (2020). ClinivalTrials.gov. NCT04031833. Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct04031833 (accessed on 22 April 2020)."},{"key":"e_1_3_5_78_1","unstructured":"U.S. National Library of Medicine. (2020). ClinivalTrials.gov. NCT03187691. Safety and PK of Oral Encochleated Amphotericin B (CAMB\/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct03187691 (accessed on 22 April 2020)."},{"key":"e_1_3_5_79_1","unstructured":"U.S. National Library of Medicine. (2020). ClinivalTrials.gov. NCT03167957. Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03167957 (accessed on 17 May 2020)."},{"key":"e_1_3_5_80_1","unstructured":"U.S. National Library of Medicine. (2022). ClinivalTrials.gov. NCT05541107. Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 (EnACT3). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05541107 (accessed on 15 September 2022)."},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2015.12.017"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2011.1230"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1039\/b820743g"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2009.01.003"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200311130812"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S54967"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-022-02384-9"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1463-1469.2000"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121184"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep19109"}],"container-title":["Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10717544.2022.2161671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:27:44Z","timestamp":1780914464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10717544.2022.2161671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/10717544.2022.2161671"],"URL":"https:\/\/doi.org\/10.1080\/10717544.2022.2161671","relation":{},"ISSN":["1071-7544","1521-0464"],"issn-type":[{"value":"1071-7544","type":"print"},{"value":"1521-0464","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=idrd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=idrd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2161671"}}